Stock Price Prediction

Purple Biotech (PPBT) stock is currently trading at $6 following a 28% drop due to a $2.8M direct offering announcement at $6 per ADS. Bulls may argue that the stock's recent 182.83% monthly gain reflects optimism around its oncology pipeline, particularly positive Phase 2 trial results for metastatic pancreatic cancer. However, the dilution from the offering and a 60.75% annual decline suggest caution despite potential long-term growth in oncology therapies.

PPBT stock is currently bearish, trading at $3.37, significantly below its recent offering price of $6. The direct offering diluted shares and triggered a sharp sell-off, compounded by weak RSI (39.64) and negative MACD (-0.18), signaling continued downward momentum. With a 60.75% decline over the past year and limited near-term catalysts, further downside risk remains likely.